NCT06474208View on ClinicalTrials.gov

A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Heart Failure
Interventions
DRUG

Formulation 1

Oral suspension of Vericiguat (BAY1021189) in single dose (SD).

DRUG

Formulation 2

Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.

DRUG

Formulation 3

Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.

DRUG

Formulation 4

Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.

DRUG

Formulation 5 (placebo)

Matching placebo of formulation 1 in SD.

Trial Locations (1)

Baden-Wurttemberg

"Clinical Research Services , Clinical Research Services Mannheim - Phase one unit"

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06474208 - A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years | Biotech Hunter | Biotech Hunter